Shinogi

door exit shut close end walk away
Biotech

F2G, Shionogi prep regulatory push after antifungal passes ph. 3

F2G and Shionogi have released phase 3 data for olorofim demonstrating its non-inferiority compared with an existing drug for invasive aspergillosis.
Will Maddox Jun 18, 2026 12:01am